218 related articles for article (PubMed ID: 36395141)
1. Somatic 9p24.1 alterations in HPV
Zhao X; Cohen EEW; William WN; Bianchi JJ; Abraham JP; Magee D; Spetzler DB; Gutkind JS; Alexandrov LB; Cavenee WK; Lippman SM; Davoli T
Proc Natl Acad Sci U S A; 2022 Nov; 119(47):e2213835119. PubMed ID: 36395141
[TBL] [Abstract][Full Text] [Related]
2. Immune evasion in HPV
William WN; Zhao X; Bianchi JJ; Lin HY; Cheng P; Lee JJ; Carter H; Alexandrov LB; Abraham JP; Spetzler DB; Dubinett SM; Cleveland DW; Cavenee W; Davoli T; Lippman SM
Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33952700
[TBL] [Abstract][Full Text] [Related]
3. Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort.
William WN; Zhang J; Zhao X; Parra ER; Uraoka N; Lin HY; Peng SA; El-Naggar AK; Rodriguez-Canales J; Song J; Gillenwater AM; Wistuba II; Myers JN; Gold KA; Ferrarotto R; Hwu P; Davoli T; Lee JJ; Heymach JV; Papadimitrakopoulou VA; Lippman SM
Cancer; 2023 Mar; 129(5):714-727. PubMed ID: 36597662
[TBL] [Abstract][Full Text] [Related]
4. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.
Tosi A; Parisatto B; Menegaldo A; Spinato G; Guido M; Del Mistro A; Bussani R; Zanconati F; Tofanelli M; Tirelli G; Boscolo-Rizzo P; Rosato A
J Exp Clin Cancer Res; 2022 Sep; 41(1):279. PubMed ID: 36123711
[TBL] [Abstract][Full Text] [Related]
5. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
[TBL] [Abstract][Full Text] [Related]
6. Oropharyngeal Squamous Cell Carcinoma Treatment in the Era of Immune Checkpoint Inhibitors.
Stern PL; Dalianis T
Viruses; 2021 Jun; 13(7):. PubMed ID: 34202255
[TBL] [Abstract][Full Text] [Related]
7. Bioinformatic analysis identifies HPV-related tumor microenvironment remodeling prognostic biomarkers in head and neck squamous cell carcinoma.
Zhou Q; Yuan O; Cui H; Hu T; Xiao GG; Wei J; Zhang H; Wu C
Front Cell Infect Microbiol; 2022; 12():1007950. PubMed ID: 36425786
[TBL] [Abstract][Full Text] [Related]
8. Uncovering immune checkpoint heterogeneity in oral squamous cell carcinoma using single cell RNA-sequencing data highlights three subgroups of patients with distinct immune phenotypes.
Le Meitour Y; Foy JP; Guinand M; Michon L; Karabajakian A; Fayette J; Saintigny P; Mahtouk K
Oral Oncol; 2024 Feb; 149():106680. PubMed ID: 38218022
[TBL] [Abstract][Full Text] [Related]
9. Identification and validation of a prognostic signature of autophagy, apoptosis and pyroptosis-related genes for head and neck squamous cell carcinoma: to imply therapeutic choices of HPV negative patients.
Nan Z; Dou Y; Chen A; Wang K; Sun J; Meng Z; Neckenig M; Ai D; Liu S; Dong Z; Ma C; Cheng Y; Qu X
Front Immunol; 2022; 13():1100417. PubMed ID: 36703967
[TBL] [Abstract][Full Text] [Related]
10. The characteristics and clinical relevance of tumor fusion burden in head and neck squamous cell carcinoma.
He L; Ren D; Lv G; Mao B; Wu L; Liu X; Gong L; Liu P
Cancer Med; 2023 Jan; 12(1):852-861. PubMed ID: 35621268
[TBL] [Abstract][Full Text] [Related]
11. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy.
Han G; Yang G; Hao D; Lu Y; Thein K; Simpson BS; Chen J; Sun R; Alhalabi O; Wang R; Dang M; Dai E; Zhang S; Nie F; Zhao S; Guo C; Hamza A; Czerniak B; Cheng C; Siefker-Radtke A; Bhat K; Futreal A; Peng G; Wargo J; Peng W; Kadara H; Ajani J; Swanton C; Litchfield K; Ahnert JR; Gao J; Wang L
Nat Commun; 2021 Sep; 12(1):5606. PubMed ID: 34556668
[TBL] [Abstract][Full Text] [Related]
12. Survival-related indicators ALOX12B and SPRR1A are associated with DNA damage repair and tumor microenvironment status in HPV 16-negative head and neck squamous cell carcinoma patients.
Li J; Tang LL; Ma J
BMC Cancer; 2022 Jun; 22(1):714. PubMed ID: 35768785
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.
Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K
Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557
[TBL] [Abstract][Full Text] [Related]
14. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.
Chen YP; Wang YQ; Lv JW; Li YQ; Chua MLK; Le QT; Lee N; Colevas AD; Seiwert T; Hayes DN; Riaz N; Vermorken JB; O'Sullivan B; He QM; Yang XJ; Tang LL; Mao YP; Sun Y; Liu N; Ma J
Ann Oncol; 2019 Jan; 30(1):68-75. PubMed ID: 30407504
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment.
Li ZX; Zheng ZQ; Wei ZH; Zhang LL; Li F; Lin L; Liu RQ; Huang XD; Lv JW; Chen FP; He XJ; Guan JL; Kou J; Ma J; Zhou GQ; Sun Y
Theranostics; 2019; 9(25):7648-7665. PubMed ID: 31695792
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.
Starzer AM; Heller G; Tomasich E; Melchardt T; Feldmann K; Hatziioannou T; Traint S; Minichsdorfer C; Schwarz-Nemec U; Nackenhorst M; Müllauer L; Preusser M; Berghoff AS; Fuereder T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338086
[TBL] [Abstract][Full Text] [Related]
17. The Microenvironment of Head and Neck Cancers: Papillomavirus Involvement and Potential Impact of Immunomodulatory Treatments.
Outh-Gauer S; Morini A; Tartour E; Lépine C; Jung AC; Badoual C
Head Neck Pathol; 2020 Jun; 14(2):330-340. PubMed ID: 32124416
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
[TBL] [Abstract][Full Text] [Related]
19. Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine.
Van den Bossche V; Zaryouh H; Vara-Messler M; Vignau J; Machiels JP; Wouters A; Schmitz S; Corbet C
Drug Resist Updat; 2022 Jan; 60():100806. PubMed ID: 35121337
[TBL] [Abstract][Full Text] [Related]
20. TMEM16A as a potential treatment target for head and neck cancer.
Okuyama K; Yanamoto S
J Exp Clin Cancer Res; 2022 Jun; 41(1):196. PubMed ID: 35668455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
